Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
咪啶酮 ONC201 治疗 AML IND125,203 的 Ph1/2 研究 (12/23/2014)
基本信息
- 批准号:10663157
- 负责人:
- 金额:$ 37.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
Survival rates (app. 30 %) of acute myeloid leukemia (AML) have not been improved over 4 decades, except in
some specialized instances. The long term aim of this study is to increase the cure rates of AML through
clinical implementation of targeting a new cellular survival mechanism, i.e. mitochondrial (mt) unfolded protein
response (mtUPR). We are proposing to conduct a clinical Phase 1/2 trial of ONC201, a first-in-class
imipridone and to confirm and further investigate the underlying novel mechanism of action (MOA). We
discovered in extensive preclinical studies that ONC201 induces apoptosis in AML but not in normal cells.
Importantly, ONC201 has great efficacy in p53-mutated AML, the most chemotherapy-resistant subset, as well
as in p53 wild-type AML. Our preclinical studies further demonstrate that ONC201 eliminates functionally-
defined leukemia stem cells in patient-derived xenografts. Early trials initiated at MD Anderson show excellent
tolerability of ONC201, micromolar plasma concentrations, and early clinical responses. We previously
reported that ONC201 induces apoptosis mediated by the transcription factor ATF4, a hallmark of integrated
stress response (ISR). However, ONC201 did not induce all characteristic molecular changes associated with
classical ISRs (e.g., ER stress), suggesting an atypical MOA to induce ATF4. As break through progress
reported in this re-submission, we have discovered that ONC201 directly binds and activates the mitochondrial
protease, ClpP, resulting in selective mitochondrial proteolysis. The resultant reduction of mt protein pools
induces so-called mt protein folding stress (mtPFS) and the protective transcriptional response against mtPFS
termed mt unfolded protein response (mtUPR). Importantly, ATF4 is known to be induced through mtUPR,
connecting our previous findings on ATF4 in a way different from classical ISRs. We here hypothesize that
AML progenitor and stem cells are more susceptible to mtPFS than normal cells, and that ONC201 is targeting
a novel point of vulnerability in AML pathobiology. The proposed clinical trial in leukemia provides a unique
opportunity to thoroughly investigate this hypothesis. We will conduct a Phase 1/2 study of ONC201 in AML
(Aim 1), and evaluate the underlying MOA (Aim 2). The Phase 1 trial will determine the safety and preliminary
efficacy of ONC201 and Phase 2 the overall response rate. Changes in ATF4, mtUPR effector proteins, mt
function and biogenesis in AML cells will be investigated using standard immunoblot and PCR methods as well
as novel tools including CyTOF (single cell proteomics). We will also determine if ClpP, ATF4 and mtUPR
effector proteins are potential biomarkers of clinical response to ONC201. Changes in clonal architecture will
be monitored by flow cytometry and single-cell DNA sequencing. Genome-wide RNAseq will also be performed
to further elucidate MOA and potential resistance. We expect these studies, which are at the cutting edge of
our evolving knowledge of mitochondrial pathophysiology, to be developed into a highly effective and novel
concept for the treatment of AML.
项目摘要/摘要
存活率(AP.30%)的急性髓系白血病(AML)在过去40年中没有改善,除了
一些特殊的实例。这项研究的长期目标是通过以下途径提高AML的治愈率
靶向一种新的细胞生存机制--线粒体未折叠蛋白的临床应用
回应(MtUPR)。我们建议进行ONC201的1/2期临床试验,这是一种一流的药物
并确认和进一步研究潜在的新的作用机制(MOA)。我们
在广泛的临床前研究中发现,ONC201可诱导AML细胞凋亡,但不能诱导正常细胞凋亡。
重要的是,ONC201对p53突变的AML也有很好的疗效,P53突变的AML也是最耐药的亚群
如P53野生型AML。我们的临床前研究进一步表明,ONC201在功能上消除了-
定义了患者来源的异种移植中的白血病干细胞。MD Anderson启动的早期试验显示非常好
ONC201的耐受性、微摩尔血浆浓度和早期临床反应。我们之前
报道称,ONC201通过转录因子ATF4诱导细胞凋亡,ATF4是整合的标志
应激反应(ISR)。然而,ONC201并没有引起与以下相关的所有特征分子变化
经典的ISR(如内质网应激),表明非典型的MOA诱导ATF4。随着突破性进展
在这次重新提交的报告中,我们发现ONC201直接结合并激活线粒体
蛋白水解酶,ClpP,导致选择性线粒体蛋白分解。由此导致的mt蛋白库的减少
诱导所谓的mt蛋白折叠应激(MtPFS)和对mtPFS的保护性转录反应
称为线粒体未折叠蛋白反应(MtUPR)。重要的是,已知ATF4是通过mtUPR诱导的,
以一种不同于经典ISR的方式将我们之前在ATF4上的发现联系起来。我们在这里假设
AML祖细胞和干细胞比正常细胞更容易受到mtPFS的影响,ONC201是靶向
急性髓系白血病病理生物学中的一个新的脆弱性。拟议的白血病临床试验提供了一种独特的
彻底研究这一假说的机会。我们将在AML中进行ONC201的1/2期研究
(目标1),并评估基本的MOA(目标2)。第一阶段试验将确定安全性和初步
ONC201的疗效和2期总缓解率。ATF4、mtUPR效应蛋白、mt
AML细胞的功能和生物发生也将使用标准的免疫印迹和聚合酶链式反应方法进行研究
作为包括单细胞蛋白质组学(CyTOF)在内的新工具。我们还将确定ClpP、ATF4和mtUPR是否
效应蛋白是临床对ONC201反应的潜在生物标志物。克隆体系结构的变化将
通过流式细胞仪和单细胞DNA测序进行监测。还将执行全基因组RNAseq
以进一步阐明MOA和潜在的抗性。我们期待着这些研究,它们处于
我们不断进化的线粒体病理生理学知识,将发展成为一种高效和新颖的
急性髓系白血病的治疗理念。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL ANDREEFF其他文献
MICHAEL ANDREEFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL ANDREEFF', 18)}}的其他基金
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
- 批准号:
10356325 - 财政年份:2022
- 资助金额:
$ 37.37万 - 项目类别:
Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML
治疗靶向 p53 重新激活诱导的 OXPHOS 依赖性和应激反应,以克服 AML 中对 Venetoclax/HMA 的耐药性
- 批准号:
10550265 - 财政年份:2022
- 资助金额:
$ 37.37万 - 项目类别:
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
咪啶酮 ONC201 治疗 AML IND125,203 的 Ph1/2 研究 (12/23/2014)
- 批准号:
9806956 - 财政年份:2019
- 资助金额:
$ 37.37万 - 项目类别:
P53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia
P53 激活作为急性髓性白血病的新治疗策略
- 批准号:
8499746 - 财政年份:2013
- 资助金额:
$ 37.37万 - 项目类别:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
联合抑制急性髓系白血病中的 CXCR4 和 FLT3-ITD 信号传导
- 批准号:
7897533 - 财政年份:2010
- 资助金额:
$ 37.37万 - 项目类别:
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
联合抑制急性髓系白血病中的 CXCR4 和 FLT3-ITD 信号传导
- 批准号:
8056055 - 财政年份:2010
- 资助金额:
$ 37.37万 - 项目类别:
Targeting Microenvironment / Leukemia Cell Interactions in CML
CML 中的靶向微环境/白血病细胞相互作用
- 批准号:
8000073 - 财政年份:2010
- 资助金额:
$ 37.37万 - 项目类别:
Non-genotoxic p53 activation as novel therapeutic concept for lymphoma
非基因毒性 p53 激活作为淋巴瘤的新治疗概念
- 批准号:
7715218 - 财政年份:2009
- 资助金额:
$ 37.37万 - 项目类别:
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
Plerixafor/G-CSF 联合索拉非尼治疗带有 FLT3-ITD Muta 的急性髓性白血病
- 批准号:
7936811 - 财政年份:2009
- 资助金额:
$ 37.37万 - 项目类别:
Plerixafor/G-CSF with Sorafenib for Acute Myelogenous Leukemia with FLT3-ITD Muta
Plerixafor/G-CSF 联合索拉非尼治疗带有 FLT3-ITD Muta 的急性髓性白血病
- 批准号:
8324135 - 财政年份:2009
- 资助金额:
$ 37.37万 - 项目类别:
相似国自然基金
Incentive and governance schenism study of corporate green washing behavior in China: Based on an integiated view of econfiguration of environmental authority and decoupling logic
- 批准号:
- 批准年份:2024
- 资助金额:万元
- 项目类别:外国学者研究基金项目
A study on prototype flexible multifunctional graphene foam-based sensing grid (柔性多功能石墨烯泡沫传感网格原型研究)
- 批准号:
- 批准年份:2020
- 资助金额:20 万元
- 项目类别:
相似海外基金
Techno-economic Feasibility Study of ClimaHtech innovative clean maritime solutions
ClimaHtech 创新清洁海事解决方案的技术经济可行性研究
- 批准号:
10098100 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Collaborative R&D
HAIRCYCLE: a pilot study to explore and test regenerative, local, bio-based and circular models for human hair waste
HAIRCYCLE:一项试点研究,旨在探索和测试人类毛发废物的再生、局部、生物基和循环模型
- 批准号:
AH/Z50550X/1 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Research Grant
(Un)Fair inequality in the labor market: A global study
(Un)劳动力市场的公平不平等:一项全球研究
- 批准号:
MR/X033333/1 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Fellowship
Expanding syphilis screening among pregnant women in Indonesia using the rapid dual test for syphilis & HIV with capacity building: The DUALIS Study
使用梅毒快速双重检测扩大印度尼西亚孕妇梅毒筛查
- 批准号:
MR/Y004825/1 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Research Grant
Norway. Neuropeptide origins; study of neuropeptide functions in choanoflagellates
挪威。
- 批准号:
BB/X018512/1 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Research Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Standard Grant
RII Track-4: NSF: Fundamental study on hydrogen flow in porous media during repetitive drainage-imbibition processes and upscaling for underground energy storage
RII Track-4:NSF:重复排水-自吸过程中多孔介质中氢气流动的基础研究以及地下储能的升级
- 批准号:
2327317 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Standard Grant
Collaborative Research: EAGER: The next crisis for coral reefs is how to study vanishing coral species; AUVs equipped with AI may be the only tool for the job
合作研究:EAGER:珊瑚礁的下一个危机是如何研究正在消失的珊瑚物种;
- 批准号:
2333604 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
- 批准号:
2346565 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Standard Grant
EAGER: Innovation in Society Study Group
EAGER:社会创新研究小组
- 批准号:
2348836 - 财政年份:2024
- 资助金额:
$ 37.37万 - 项目类别:
Standard Grant